ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

ASN / Education & Meetings / Kidney Week /

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-PO595

Health-Related Quality of Life (HRQoL) in Adults with Primary Glomerular Diseases in India

Session Information

Category: Glomerular Diseases

  • 1402 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

  • Grewal, Amritesh, All India Institute of Medical Sciences, New Delhi, Delhi, India
  • Bansal, Bhavik, All India Institute of Medical Sciences, New Delhi, Delhi, India
  • Subbiah, Arunkumar, All India Institute of Medical Sciences, New Delhi, Delhi, India
  • Bhowmik, Dipankar M., All India Institute of Medical Sciences, New Delhi, Delhi, India
  • Agarwal, Sanjay K., All India Institute of Medical Sciences, New Delhi, Delhi, India
  • Bagchi, Soumita, All India Institute of Medical Sciences, New Delhi, Delhi, India
Background

There is paucity of information about the health-related quality of life (HRQOL) of patients with glomerular diseases.

Methods

We used PROMIS 29 v2.1 (Patient-Reported Outcomes Measurement Information System) tool to assess the HRQoL impact of primary glomerular diseases in adult patients, under the following domains: physical function, anxiety, fatigue, depression, sleep disturbance, ability to participate in social roles and activities, and pain interference in daily activities. A composite score representing the patient's global HRQoL was calculated using T scores (mean=50, standard deviation=10) of individual domains derived from patient responses. Multivariable linear regression models were evaluated for all domains and composite scores independently.

Results

301 patients were recruited (100 minimal change disease/focal segmental glomerulosclerosis, 75 membranous nephropathy, 109 IgA nephropathy, and 17 membrano-proliferative glomerulonephritis). Mean T-scores were: physical function - 48 (47.6-49.9), fatigue - 48.7 (47.6-49.9), anxiety - 51.4 (50.3-52.6), sleep impairment - 44 (42.9-45), depression - 50.1 (49-51.2), ability to participate in social roles and activities - 55.6 (54.5-56.7), hindrance in daily activities due to pain - 51 (50-52).
Worse physical function was significantly associated with female sex (β=3.28), low eGFR (<60ml/min/1.73m2) (β=2.45), unemployed status (β=2.12), obesity (BMI>30) (β=4.4), and edema (β=2.71); fatigue with female sex (β=4.9), low eGFR (β=3.51) and obesity (β=7.41); anxiety with recent steroid use (β=2.61), female sex (β=3.74), and low eGFR (β=2.74) and sleep impairment with recent steroid use (β=3.46), female sex (β=2.56), lower eGFR (β=3.37) and edema (β=4.02). Depression was higher with obesity (β=5.0) and low eGFR (β=2.4) and pain interference with female gender (β=5.95), low eGFR (β=2.38), and obesity (β=4.0). Decreased ability to perform social roles was seen in females (β=4.6), and obese individuals (β=2.58).
Lower composite scores (worse global quality of life) were associated with female sex (β= 3.65), lower eGFR (β= 3.14), and obesity (β=4.02).

Conclusion

Glomerular diseases adversely impact quality of life. Female sex, lower renal function, obesity, clinically apparent edema, and recent steroid use correlate with higher morbidity.